Keyphrases
30-day Mortality
21%
Adverse Events
13%
All-cause Mortality
19%
Antibiotic Duration
15%
Antibiotic Treatment
17%
Antibiotics
31%
Bacteremia
43%
Bacterial Infection
14%
Bloodstream Infection
26%
BNT162b2 Vaccine
15%
Carbapenem-resistant Acinetobacter Baumannii
16%
Carbapenems
16%
Clinical Failure
14%
Clinical Outcomes
28%
Clostridium Difficile Infection
15%
Colistin
32%
Combination Therapy
14%
Confidence Interval
64%
COVID-19
41%
External Validity
14%
Febrile Neutropenia
15%
Fever
14%
Gram-negative Bloodstream Infections
12%
Hospitalized Patients
15%
Infectious Diseases
17%
Israel
21%
Kidney Transplant Recipients
21%
Lactams
25%
Long COVID
15%
Meta-analysis
59%
Meta-analysis of Randomized Controlled Trials
29%
Methicillin-resistant Staphylococcus Aureus
16%
Monotherapy
18%
Multivariate Analysis
15%
No Significant Difference
15%
Odds Ratio
25%
Older Adults
28%
Older Patients
13%
Prospective Cohort Study
18%
Randomized Clinical Trial
13%
Randomized Controlled Trial
70%
Relative Risk
17%
Retrospective Cohort Study
16%
Risk Factors
30%
Risk Ratio
19%
Severe Infection
16%
Staphylococcus Aureus Bacteremia
21%
Systematic Meta-analysis
65%
Urinary Tract Infection
15%
Vancomycin
25%
Pharmacology, Toxicology and Pharmaceutical Science
Acinetobacter Baumannii
13%
Adverse Event
20%
All Cause Mortality
24%
Antibiotic Agent
35%
Antibiotic Therapy
25%
Antibiotics
69%
Antiinfective Agent
14%
Bacteremia
45%
Bacterial Infection
15%
Bloodstream Infection
36%
Carbapenem
41%
Carbapenem Derivative
12%
Clinical Trial
14%
Clostridium Difficile Infection
11%
Cohort Study
25%
Colistimethate
33%
Combination Therapy
15%
Cotrimoxazole
9%
COVID-19 Vaccine
9%
Cross-Sectional Study
13%
Disease
16%
Febrile Neutropenia
14%
Gram Negative Bacterium
14%
Gram Negative Sepsis
11%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
10%
Infection
97%
Infectious Agent
17%
Lactam
21%
Meropenem
15%
Methicillin Resistant Staphylococcus Aureus Infection
19%
Methicillin-Resistant Staphylococcus Aureus
16%
Monotherapy
18%
Observational Study
11%
Penicillinase
9%
Piperacillin Plus Tazobactam
10%
Placebo
11%
Prevalence
9%
Prospective Cohort Study
11%
Pseudomonas aeruginosa
14%
Randomized Clinical Trial
12%
Randomized Controlled Trial
91%
Retrospective Study
36%
SARS Coronavirus
11%
Sepsis
19%
Staphylococcal Bacteremia
13%
Staphylococcus Aureus
8%
Symptom
13%
Urinary Tract Infection
14%
Vaccination Policy
11%
Vancomycin
25%
Medicine and Dentistry
Acinetobacter Baumannii
9%
Adverse Event
9%
All Cause Mortality
14%
Antibiotic Therapy
36%
Antibiotics
45%
Antiinfective Agent
21%
Arm
8%
Bacteremia
37%
Bacterial Infection
14%
Bloodstream Infection
38%
Carbapenem
27%
Clinical Trial
12%
Cohort Analysis
13%
Colistimethate
13%
COVID-19
37%
Cross Sectional Study
11%
Diagnosis
8%
Disease
11%
Gram-Negative Bacteria
12%
Hematopoietic Stem Cell
8%
Hemodialysis
8%
Immunosuppressive Treatment
9%
Infection
100%
Intensive Care Unit
12%
Internal Medicine
8%
Kidney Graft
18%
Meropenem
8%
Meta-Analysis
47%
Methicillin Resistant Staphylococcus Aureus
8%
Monotherapy
8%
Multivariate Analysis
8%
Observational Study
14%
Odds Ratio
20%
Pathogen
20%
Piperacillin/Tazobactam
8%
Postcovid Syndrome
12%
Prospective Cohort Study
8%
Pseudomonas aeruginosa
8%
Randomized Controlled Trial
56%
Retrospective Cohort Study
13%
Retrospective Study
42%
Sepsis
9%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Staphylococcal Bacteremia
11%
Subgroup Analysis
8%
Symptom
10%
Systematic Review
46%
Transplantation
11%
Urinary System
8%
Urinary Tract Infection
13%